QT Prolongation: May prolong QT interval. Monitor ECG in patients with a history of QT prolongation or who are taking medications which prolong the QT interval.
- TRADE NAME: Egaten (Novartis)
- INDICATIONS: Indicated for the treatment of fascioliasis in patients 6 years of age and older.
- SYNONYM: Egaten
- CLASS: Anthelmintic
- HALF-LIFE: 8 hours
- FDA APPROVAL DATE: 02/13/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ErdafitinibCYP2C19 substrates - PREGNANCY: There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 01/31/2024
